Thromb Haemost 1998; 80(06): 976-981
DOI: 10.1055/s-0037-1615398
Letters to the Editor
Schattauer GmbH

Secreted ADP Plays a Central Role in Thrombin-induced Phospholipase D Activation in Human Platelets

Elizabeth A. Martinson*
,
Stephan Scheible*
,
Alexandra Marx-Grunwitz
1   From the Rudolf-Buchheim-Institut für Pharmakologie, Justus-Liebig-Universität Gießen, Gießen, Germany
,
Peter Presek
1   From the Rudolf-Buchheim-Institut für Pharmakologie, Justus-Liebig-Universität Gießen, Gießen, Germany
› Author Affiliations
Further Information

Publication History

Received 10 February 1998

Accepted after resubmission 20 August 1998

Publication Date:
07 December 2017 (online)

Summary

Thrombin and other agonists that induce secretion and aggregation in human platelets also activate phospholipase D (PLD), but the signaling cascade leading to activation of PLD in human platelets is not yet clear. We have determined that apyrase, which scavenges ADP secreted during platelet activation, is able to block or reduce the PLD activation stimulated by low (0.1 U/ml or less) or high (0.3-1.0 U/ml) concentrations of thrombin, respectively. Neither ADP (up to 100 μM) nor its more potent analogue 2-methylthio-ADP (up to 100 μM), however, are able to stimulate PLD alone, and even the addition of fibrinogen, which results in platelet aggregation, is not sufficient for PLD activation. In contrast, ADP is able to stimulate PLD in the presence of low concentrations of thrombin that alone have little or no effect, suggesting ADP may play an amplifying role in platelet PLD activation. This hypothesis is supported by the finding that the purinergic receptor antagonist ARL 66096, an ATP analogue, reduces in a concentration-dependent fashion the PLD response to thrombin (IC50 = 28 nM with 0.1 U/ml thrombin). ARL 66096 also abolishes the PLD activation by ADP observed in the presence of low concentrations of thrombin, confirming that the antagonist inhibits an ADP-dependent component of the response. In addition, the thromboxane A2 receptor agonist U46619 activates PLD, and this response is markedly reduced by ARL 66096. Concomitantly, phosphorylation of the protein kinase C substrate pleckstrin in response to thrombin or U46619 is partially or totally inhibited by ARL 66096, respectively, consistent with ADP stimulation of protein kinase C being involved in the PLD response to these agonists. Based on these findings, we conclude that ADP secretion and activation of purinergic ADP receptors is an important amplification mechanism in the signal transduction pathways leading to PLD activation in human platelets.

* The first two authors made equal contributions.


 
  • References

  • 1 Billah MM. Phospholipase D and cell signaling. Curr Opin Immunol 1993; 5: 114-23.
  • 2 Exton JH. Phospholipase D: enzymology, mechanisms of regulation, and function. Physiol Rev 1997; 77: 303-20.
  • 3 Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1994; 1212: 26-42.
  • 4 Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive lipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-80.
  • 5 Werner MH, Bielawska AE, Hannun YA. Multiphasic generation of diacylglycerol in thrombin-activated human platelets. Biochem J 1992; 282: 815-20.
  • 6 Olson SC, Lambeth JD. Biochemistry and cell biology of phospholipase D in human neutrophils. Chem Phys Lipid. 1996; 80: 3-19.
  • 7 Waite KA, Wallin R, Qualliotine-Mann D, McPhail LC. Phosphatidic acid-mediated phosphorylation of the NADPH oxidase component p47-phox. Evidence that phosphatidic acid may activate a novel protein kinase. J Biol Chem 1997; 272: 15569-78.
  • 8 Roth MG, Sternweis PC. The role of lipid signaling in constitutive membrane traffic. Curr Opin Cell Biol 1997; 9: 519-26.
  • 9 Bi K, Roth MG, Ktistakis NT. Phosphatidic acid formation by phospholipase D is required for transport from the endoplasmic reticulum to the Golgi complex. Curr Biol 1997; 7: 301-7.
  • 10 Rubin R. Phosphatidylethanol formation in human platelets: evidence for thrombin-induced activation of phospholipase D. Biochem Biophys Res Commun 1988; 156: 1090-6.
  • 11 Huang R, Kucera GL, Rittenhouse SE. Elevated cytosolic Ca2+ activates phospholipase D in human platelets. J Biol Chem 1991; 266: 1652-5.
  • 12 Petty AC, Scrutton MC. Release of choline metabolites from human platelets: evidence for activation of phospholipase D and of phosphatidylcholine-specific phospholipase C. Platelets 1993; 4: 23-9.
  • 13 Martinson EA, Scheible S, Presek P. Inhibition of phospholipase D of human platelets by protein tyrosine kinase inhibitors. Cell Mol Biol 1994; 40: 627-34.
  • 14 Martinson EA, Scheible S, Greinacher A, Presek P. Platelet phospholipase D is activated by protein kinase C via an integrin alphaIIb-beta3-independent mechanism. Biochem J 1995; 310: 623-8.
  • 15 Kiss Z. Regulation of phospholipase D by protein kinase C. Chem Phys Lipids 1996; 80: 81-102.
  • 16 Cockcroft S. Phospholipase D: regulation by GTPases and protein kinase C and physiological relevance. Prog Lipid Res 1996; 35: 345-70.
  • 17 Morris AJ, Engebrecht J, Frohman MA. Structure and regulation of phospholipase D. Trends Biochem Sci 1996; 17: 182-5.
  • 18 Hammond SM, Altshuller YM, Sung TC, Rudge SA, Rose K, Engebrecht J, Morris AJ, Frohman MA. Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J Biol Chem 1995; 270: 29640-3.
  • 19 Hammond SM, Jenco JM, Nakashima S, Cadwallader K, Gu Q, Cook S, Nozawa Y, Prestwich GD, Frohman MA, Morris AJ. Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4,5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. J Biol Chem 1997; 272: 3860-8.
  • 20 Lopez I, Arnold RS, Lambeth JD. Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem 1998; 273: 12846-52.
  • 21 Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69: 58-178.
  • 22 Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995; 35: 541-79.
  • 23 Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994; 113: 1057-63.
  • 24 Olbrich C, Aepfelbacher M, Siess W. Epinephrine potentiates calcium mobilization and activation of protein kinases in platelets stimulated by ADP through a mechanism unrelated to phospholipase C. Cell Signal 1989; 1: 483-92.
  • 25 Pulcinelli FM, Ashby B, Gazzaniga PP, Daniel JL. Protein kinase C activation is not a key step in ADP-mediated exposure of fibrinogen receptors on human platelets. FEBS Lett 1995; 364: 87-90.
  • 26 Imaoka T, Lynham JA, Haslam RJ. Purification and characterization of the 47,000-dalton protein phosphorylated during degranulation of human platelets. J Biol Chem 1983; 258: 11404-14.
  • 27 Hannun YA, Greenberg CS, Bell RM. Sphingosine inhibition of agonist-dependent secretion and activation of human platelets implies that protein kinase C is a necessary and common event of the signal transduction pathway. J Biol Chem 1987; 262: 13620-6.
  • 28 Walker TR, Watson SP. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J 1993; 289: 277-82.
  • 29 Chiang TM. Activation of phospholipase D in human platelets by collagen and thrombin and its relationship to platelet aggregation. Biochim Biophys Acta 1994; 1224: 147-55.
  • 30 Benistant C, Rubin R. Ethanol inhibits thrombin-induced secretion by human platelets at a site distinct from phospholipase C or protein kinase C. Biochem J 1990; 269: 489-97.
  • 31 Vial C, Hechler B, Leon C, Cazenave J, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-4.
  • 32 Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 26-30.
  • 33 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
  • 34 Mills DC. ADP receptors on platelets. Thromb Haemost 1996; 76: 835-56.
  • 35 Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-9.
  • 36 Crabos M, Fabbro D, Stabel S, Erne P. Effect of tumour-promoting phorbol ester, thrombin and vasopressin on translocation of three distinct protein kinase C isoforms in human platelets and regulation by calcium. Biochem J 1992; 288: 891-6.
  • 37 Grabarek J, Raychowdhury M, Ravid K, Kent KC, Newman PJ, Ware JA. Identification and functional characterization of protein kinase C isozymes in platelets and HEL cells. J Biol Chem 1992; 267: 10011-7.
  • 38 Wang F, Naik UP, Ehrlich YH, Freyberg Z, Osada S, Ohno S, Kuroki T, Suzuki K, Kornecki E. A new protein kinase C, nPKC eta‘, and nPKC theta are expressed in human platelets: involvement of nPKC eta’ and nPKC theta in signal transduction stimulated by PAF. Biochem. Biophys Res Commun 1993; 191: 240-6.
  • 39 Chang JD, Xu Y, Raychowdhury MK, Ware JA. Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets. J Biol Chem 1993; 268: 14208-14.
  • 40 Baldassare JJ, Henderson PA, Burns D, Loomis C, Fisher GJ. Translocation of protein kinase C isozymes in thrombin-stimulated human platelets. Correlation with 1,2-diacylglycerol levels. J Biol Chem 1992; 267: 15585-90.
  • 41 Nakanishi H, Exton JH. Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J Biol Chem 1992; 267: 16347-54.
  • 42 Ways DK, Cook PP, Webster C, Parker PJ. Effect of phorbol esters on protein kinase C-zeta. J Biol Chem 1992; 267: 4799-805.
  • 43 Coorssen JR, Haslam RJ. GTP gamma S and phorbol ester act synergistically to stimulate both Ca2+-independent secretion and phospholipase D activity in permeabilized human platelets. Inhibition by BAPTA and analogues. FEBS Lett 1993; 316: 170-4.
  • 44 Coorssen JR. Phospholipase activation and secretion: evidence that PLA2, PLC, and PLD are not essential to exocytosis. Am J Physiol 1996; 270: C1153-63.
  • 45 Smyth SS, Hillery CA, Parise LV. Fibrinogen binding to purified platelet glycoprotein IIb-IIIa (integrin alphaIIb-beta3) is modulated by lipids. J Biol Chem 1992; 267: 15568-77.